Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
The Wellcome Trust

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 24 March 2006:
Vol. 311. no. 5768, p. 1669
DOI: 10.1126/science.311.5768.1669i
Prev | Table of Contents | Next

This Week in Science

One of the major hurdles in cancer therapy is delivering drugs efficiently to the tumor cell target. Thorne et al. (p. 1780) addressed this problem by designing a "Trojan horse" therapy in which immune effector cells that naturally migrate to tumors (cytokine-induced killer, or CIK cells) were used to deliver a potent oncolytic virus (vaccinia) to tumors growing in mice. The CIK cells transported the virus deep within the tumors to provide a uniform distribution of infection. The viral infection in turn enhanced tumor cell killing by the CIK cells and significantly inhibited tumor growth. Although each component of the therapy had been shown previously to have antitumor activity, the combination proved to be much more effective.




ADVERTISEMENT
Click Me!

ADVERTISEMENT
Click Me!

To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)